Chapel Hill startup lands rights to drug offering hope to cystic fibrosis patients
The firm received the license from Laurel Therapeutics, a global clinical-stage biopharmaceutical company in Hangzhou China. PBA will use its proprietary technology – an organoid platform using primary cells — to identify subpopulations of patients in which the drug candidate is effective.
Read More
